The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.
Patients with diffuse large B-cell lymphoma (DLBCL) most commonly present with masses involving the lymph nodes in the neck, abdomen, or mediastinum, and with symptoms that include weight loss and night sweats.
However, a new case report underscores the variability of the disease. In the case, a patient was found to have a large cystic left retroperitoneal mass that was later diagnosed as DLBCL. The report was published in Cureus.
The World Health Organization has recognized a “relatively rare” subtype of DLBCL in which patients present with a mass in the setting of chronic inflammation or in the growth wall of a preexisting cyst, noted the study authors. Yet, the patient described in the report had neither chronic inflammation nor a preexisting cyst.
“To our knowledge, this is the first case to be reported adding to the already diverse presentation of the disease,” the authors wrote.
The patient was a 53-year-old Black woman with several preexisting health conditions, including chronic iron deficiency anemia, asthma, hypertension, and type 2 diabetes. When she arrived at the hospital, she complained about fatigue, shortness of breath, and pain on the left side of her abdomen. Those symptoms had been going on for a month, but now the patient was also experiencing fever and diarrhea.
Upon examination, her physicians noted a large soft palpable mass in the left upper abdominal quadrant. A subsequent CT scan showed a large mass measuring 21 by 15.5 by 22 cm. It was a predominantly cystic, left retroperitoneal mass with thickened, enhancing walls that was so large it had displaced her left kidney and stomach. The scan also showed multiple enlarged retroperitoneal/para-aortic lymph nodes, the authors said.
After a meeting of a multidisciplinary team, the patient underwent a biopsy, during which surgeons also drained 1.4 L of fluid from the cystic component of the mass. The drainage led to a marked improvement of the patient’s symptoms, the authors said.
The biopsy and cytology confirmed that the patient had large B-cell lymphoma, but because the drainage had relieved her symptoms, her physicians decided to refer the patient for chemotherapy instead of performing surgery to remove the mass.
The patient completed her first cycle of chemotherapy, but then she suffered a fall at home during which she hit the left upper quadrant of her abdomen. A CT scan at the hospital suggested splenic rupture. At that point, the patient underwent surgery to remove both her spleen and the cystic mass. The patient was discharged 7 days later and at the study’s writing, was continuing to undergo outpatient chemotherapy.
The authors said their case shows that, even though rare, hematological cancers should be considered when encountering cystic masses of unknown origin. They said a thorough evaluation with a biopsy is also necessary before surgery is warranted.
“Ultimately, these patients will require chemotherapy which remains the standard of care and surgery may still be required for symptomatic relief for some patients,” they said.
Reference
Genualdi J, Orach T, Gumbs S, Ausqui G, Donaldson B, Ramcharan A. Traumatic rupture of cystic left retroperitoneal mass: an atypical presentation of diffuse large B-cell lymphoma. Cureus. Published online April 18, 2023. doi:10.7759/cureus.37797
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More